上交所百家民企大调研：积极拥抱人工智能成潮流

Core Viewpoint - The Shanghai Stock Exchange (SSE) is actively conducting a large-scale research initiative on private enterprises, focusing on how these companies are embracing artificial intelligence (AI) technology to enhance their operations and competitiveness [1][2]. Group 1: AI Integration in Private Enterprises - Private enterprises listed on the Shanghai Stock Exchange are proactively integrating AI technologies, with companies like Fosun Pharma leveraging global leading AI models to enhance drug development processes [4]. - Fosun Pharma has launched the PharmAID decision-making AI platform, which addresses various challenges in drug research, including literature review and market analysis [4]. - Dragon Flag Technology is focusing on AI/AR smart glasses as a key growth area, indicating a significant shift towards AI-driven products in the consumer electronics sector [5][6]. Group 2: Research and Development Insights - The SSE's research initiative aims to identify the main challenges faced by private enterprises and explore how capital market tools can help overcome these obstacles [2][9]. - Companies have expressed the need for expanded AI databases and reduced financing costs to enhance AI applications in their operations [9]. - Fosun Pharma's Vice Chairman highlighted the necessity of increasing data volume for effective AI training in drug development [9]. Group 3: Growth of Private Enterprises in Shanghai - Private enterprises constitute over 50% of the companies listed on the Shanghai Stock Exchange, with a total market value of approximately 14 trillion yuan [12]. - In the first three quarters of 2024, private enterprises in Shanghai achieved a revenue of 5.37 trillion yuan, with a compound annual growth rate of 8.7% over the past three years [12]. - The investment in R&D by these enterprises reached 193.5 billion yuan, reflecting a compound annual growth rate of 13.4% [12].